Event

A faculty of experts (David Price [Singapore; moderator]; Ken Chapman [Canada]; Dave Singh [UK]) will discuss the new evidence informing the role of LABA/LAMA and LABA/LAMA/ICS therapy in COPD management. The importance of personalized COPD management will be discussed, including clinical considerations and consensus regarding use of ICS, and evidence-based approaches to ICS withdrawal. *An Industry Theater presentation at the ATS 2018 International Conference. This program is sponsored by Novartis Pharma AG. It is only available to attendees not from the United States.